Paclitaxel/Radiotherapy/Cisplatino for cervical cancer

Phase 2

• Conditions: Cervical cancer; Uterine Cervical Neoplasms; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Neoplasms

• Registration Number: RPCEC00000239
• Lead Sponsor: Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Women older than 18 years
2. Clinical and histological diagnosis of CaCU EC IIB-IVA.
3. Histology of epidermoid carcinoma, adenocarcinoma, adenosquamous.
4. ECOG 0-2.
5. Patients with no history of Hepatic insufficiency or creatinine clearance less than 30mil / min.
6. Patients without sensory or motor neuropathy from any cause

Exclusion Criteria

1. Histology of small cells.
2. ECOG 3 or greater.
3. Diagnosis of second primary cancer.
4. Patients with diagnosed pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete response (RECIST 1.1). Measuring time: 12 weeks.

Secondary Outcome Measures

Name	Time	Method
Adverse Events (According to Common Terminology of Criteria for Adverse Events (CTCAE) version 3). Measurement time: Every week until week 12.